Form 8-K - Current report:
SEC Accession No. 0001367644-23-000002
Filing Date
2023-01-05
Accepted
2023-01-05 17:27:31
Documents
15
Period of Report
2023-01-05
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20230105.htm   iXBRL 8-K 36889
2 EX-99.1 emergentbiosolutionssign.htm EX-99.1 7496
6 GRAPHIC emergentbiosolutionssign001.jpg GRAPHIC 296265
7 GRAPHIC emergentbiosolutionssign002.jpg GRAPHIC 205505
  Complete submission text file 0001367644-23-000002.txt   880623

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20230105.xsd EX-101.SCH 1965
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20230105_lab.xml EX-101.LAB 25154
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20230105_pre.xml EX-101.PRE 13100
9 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20230105_htm.xml XML 11453
Mailing Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879
Business Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 23512541
SIC: 2834 Pharmaceutical Preparations